Overview
FAS encodes a cell surface receptor involved in the induction of apoptosis. FAS mutations are common in DLBCL and may be more frequent in primary gastric DLBCL.1,2 Mutations also occur in FL at a lower rate.3 Although reported in one BL study,4 overall the evidence for FAS mutations in BL remains sparse. Mutations in FAS often lead to a loss of function, making lymphoma cells resistant to Fas ligand-induced apoptosis, thereby allowing malignant cells to evade immune surveillance.5 In mouse models, Fas mutations led to a significantly shorter lymphoma-specific survival and reduced sensitivity to chemotherapy.5
Experimental Evidence
Driver mutations affecting this gene in FL/DLBCL have been experimentally demonstrated to cause a reduction or loss of function (LOF).6
Relevance tier by entity
Cannot include /table1_FAS.md - does not exist yet
Mutation incidence in large patient cohorts (GAMBL reanalysis)
Cannot include /DLBCL_FAS.md - does not exist yet
Cannot include /FL_FAS.md - does not exist yet
Mutation pattern and selective pressure estimates
Cannot include /dnds_FAS.md - does not exist yet
Cannot include /browser_FAS.md - does not exist yet
Expression
Cannot include /mermaid_FAS.md - does not exist yet